Fig. 1
FTVII-mediated α(1,3)-exofucosylation of BMSCs. A The expression of CD44 on the surface of FTVII-unmodified and FTVII-modified BMSCs was detected by flow cytometry with APC-conjugated anti-CD44 antibody. B The efficiency of exofucosylation modification on BMSCs was evaluated by the reactivity with APC-conjugated anti-HECA452 antibody by the flow cytometry. The result showed that sLeX was hardly expressed in FTVII-unmodified BMSCs, but was highly expressed in the FTVII-modified BMSCs. C Western blotting analysis of HECA452 expression of FTVII-unmodified BMSCs and FTVII-modified BMSCs, the positive bands were at  ~ 70KD and ~ 35KD. GAPDH was used as a protein loading control. D The cell viability test of unmodified BMSCs and FTVII-modified BMSCs by trypan blue staining. FTVII: fucosyltransferase VII; Control: the isotype control group; Unmodified BMSCs: BMSCs without fucosylation modification; FTVII-modified BMSCs: BMSCs modified with fucosyltransferase VII; CD44-APC: APC-conjugated anti mouse CD44; HECA452-APC: APC-conjugated anti-mouse HECA452